Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Search

Page Path
HOME > Search
14 "Hyuk Yoon"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
Original Article
A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease
Kwang Woo Kim, Hyoun Woo Kang, Seong-Joon Koh, Hyuk Yoon, Sihyun Kim, Yukyung Jun, Hyun Jung Lee, Jong Pil Im, Young Soo Park, Ji Won Kim, Joo Sung Kim, Seoul National University Inflammatory Bowel Disease Research Network (SIRN)
Received January 5, 2025  Accepted April 2, 2025  Published online June 23, 2025  
DOI: https://doi.org/10.5217/ir.2025.00001    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
We compared intravenous and subcutaneous infliximab (IFX) as treatment for inflammatory bowel disease (IBD).
Methods
This retrospective, multicenter, observational study enrolled patients treated with either intravenous or subcutaneous IFX. Sequential parameters were compared at baseline, 6 months, and 12 months following the initiation of treatment with either type of IFX. The primary outcome was the comparison of the IFX trough levels after 12 months of treatment.
Results
In total, 183 participants were included in this study. After 6 months, the subcutaneous group exhibited significant differences compared to the intravenous group; in terms of clinical disease activity (0% vs. 15%, P= 0.007) and IFX trough level (21.72 ± 8.71 μg/mL vs. 7.70 ± 16.65 μg/mL, P= 0.002). After 12 months, subcutaneous, as compared to intravenous, achieved improved clinical disease activity (0% vs. 15%, P= 0.044) and IFX trough level (20.41 ± 12.91 μg/mL vs. 7.06 ± 6.81 μg/mL, P< 0.001). Analyzing the sequential changes compared with baseline data within each group, we observed significant alterations in subcutaneous; 6 months fecal calprotectin (676.3 ± 976.6 μg/g vs. 253.9 ± 483.9 μg/g, P= 0.014), 6 months IFX trough level (7.00 ± 5.67 μg/mL vs. 18.44 ± 6.34 μg/mL, P= 0.026), and 12 months IFX trough level (7.00 ± 5.67 μg/mL vs. 21.33 ± 4.50 μg/mL, P= 0.034).
Conclusions
This study indicates the potential suitability of subcutaneous IFX as an alternative treatment option for IBD.
  • 354 View
  • 52 Download
Close layer
Corrigendum
IBD
Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(2):273-273.   Published online April 28, 2023
DOI: https://doi.org/10.5217/ir.2021.00173.e
Corrects: Intest Res 2023;21(1):137
PDFPubReaderePub
  • 2,362 View
  • 149 Download
Close layer
Original Articles
IBD
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN)
Intest Res 2023;21(2):244-251.   Published online August 8, 2022
DOI: https://doi.org/10.5217/ir.2022.00057
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This study aims to evaluate the effect of concomitant AS on IBD outcomes.
Methods
Among the 4,722 patients with IBD who were treated in 3 academic hospitals from 2004 to 2021, 55 were also diagnosed with AS (IBD-AS group). Based on patients’ electronic medical records, the outcomes of IBD in IBD-AS group and IBD group without AS (IBD-only group) were appraised.
Results
The proportion of patients treated with biologics or small molecule therapies was significantly higher in IBD-AS group than the proportion in IBD-only group (27.3% vs. 12.7%, P= 0.036). Patients with both ulcerative colitis and AS had a significantly higher risk of biologics or small molecule therapies than patients with only ulcerative colitis (P< 0.001). For univariable logistic regression, biologics or small molecule therapies were associated with concomitant AS (odds ratio, 4.099; 95% confidence interval, 1.863–9.021; P< 0.001) and Crohn’s disease (odds ratio, 3.552; 95% confidence interval, 1.590–7.934; P= 0.002).
Conclusions
Concomitant AS is associated with the high possibility of biologics or small molecule therapies for IBD. IBD patients who also had AS may need more careful examination and active treatment to alleviate the severity of IBD.

Citations

Citations to this article as recorded by  
  • Author's Reply: “Association of early antibiotic use with risk of ulcerative colitis”
    Junseok Park, Sungjin Woo, Seong-Joon Koh
    Digestive and Liver Disease.2025; 57(3): 795.     CrossRef
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • 5,876 View
  • 455 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
IBD
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(1):137-147.   Published online July 12, 2022
DOI: https://doi.org/10.5217/ir.2021.00173
Correction in: Intest Res 2023;21(2):273
AbstractAbstract PDFPubReaderePub
Background/Aims
We investigated the real-world effectiveness and safety of ustekinumab (UST) as induction treatment for Koreans with Crohn’s disease (CD).
Methods
CD patients who started UST were prospectively enrolled from 4 hospitals in Korea. All enrolled patients received intravenous UST infusion at week 0 and subcutaneous UST injection at week 8. Clinical outcomes were assessed using Crohn’s Disease Activity Index (CDAI) scores at weeks 8 and 20 among patients with active disease (CDAI ≥150) at baseline. Clinical remission was defined as a CDAI <150, and clinical response was defined as a reduction in CDAI ≥70 points from baseline. Safety and factors associated with clinical remission at week 20 were also analyzed.
Results
Sixty-five patients were enrolled between January 2019 and December 2020. Among 49 patients with active disease at baseline (CDAI ≥150), clinical remission and clinical response at week 8 were achieved in 26 (53.1%) and 30 (61.2%) patients, respectively. At week 20, 27 (55.1%) and 35 (71.4%) patients achieved clinical remission and clinical response, respectively. Twenty-seven patients (41.5%) experienced adverse events, with serious adverse events in 3 patients (4.6%). One patient (1.5%) stopped UST therapy due to poor response. Underweight (body mass index <18.5 kg/m2) (odds ratio [OR], 0.085; 95% confidence interval [CI], 0.014–0.498; P=0.006) and elevated C-reactive protein at baseline (OR, 0.133; 95% CI, 0.022–0.823; P=0.030) were inversely associated with clinical remission at week 20.
Conclusions
UST was effective and well-tolerated as induction therapy for Korean patients with CD.

Citations

Citations to this article as recorded by  
  • One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study
    Chang Kyun Lee, Won Moon, Jaeyoung Chun, Eun Soo Kim, Hyung Wook Kim, Hyuk Yoon, Hyun Soo Kim, Yoo Jin Lee, Chang Hwan Choi, Yunho Jung, Sung Chul Park, Geun Am Song, Jong Hun Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jong Min Choi, Byong Duk Ye
    Inflammatory Bowel Diseases.2025; 31(5): 1306.     CrossRef
  • Characteristics and outcomes of portal vein thrombosis in patients with inflammatory bowel disease in Korea
    Ki Jin Kim, Su-Bin Song, Jung-Bin Park, June Hwa Bae, Ji Eun Baek, Ga Hee Kim, Min-Jun Kim, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Chang Sik Yu, Yong-Sik Yoon, Jong-Lyul Lee, Min Hy
    The Korean Journal of Internal Medicine.2025; 40(2): 243.     CrossRef
  • The ‘totality of evidence’ and ‘extrapolation’ of SB17, a ustekinumab biosimilar
    Jae Hee Cheon, Byong Duk Ye, Alessandro Armuzzi, Florian Rieder, Giampiero Girolomoni, Luis Puig, Hojung Jung, Steven R. Feldman
    Expert Opinion on Biological Therapy.2025; 25(6): 615.     CrossRef
  • Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
    Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Approach to loss of response to advanced therapies in inflammatory bowel disease
    Nikil Vootukuru, Abhinav Vasudevan
    World Journal of Gastroenterology.2024; 30(22): 2902.     CrossRef
  • Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
    Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
    Intestinal Research.2023; 21(2): 273.     CrossRef
  • 5,246 View
  • 447 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
IBD
Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study
Eun Soo Kim, Chung Hyun Tae, Sung-Ae Jung, Dong Il Park, Jong Pil Im, Chang Soo Eun, Hyuk Yoon, Byung Ik Jang, Haruhiko Ogata, Kayoko Fukuhara, Fumihito Hirai, Kazuo Ohtsuka, Jing Liu, Qian Cao, on behalf of the Clinical Research Committee of the Asian Organization for Crohn’s and Colitis
Intest Res 2022;20(2):192-202.   Published online April 29, 2022
DOI: https://doi.org/10.5217/ir.2020.00150
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Complementary and alternative medicine (CAM) is prevalent in East Asia. However, information on CAM in East Asian patients with inflammatory bowel disease (IBD) is scarce. We aimed to profile the prevalence and pattern of CAM use among East Asian IBD patients and to identify factors associated with CAM use. We also compared physicians’ perspectives on CAM.
Methods
Patients with IBD from China, Japan, and South Korea were invited to complete questionnaires on CAM use. Patient demographic and clinical data were collected. Logistic regression analysis was applied for predictors of CAM use. Physicians from each country were asked about their opinion on CAM services or products.
Results
Overall, 905 patients with IBD participated in this study (China 232, Japan 255, and South Korea 418). Approximately 8.6% of patients with IBD used CAM services for their disease, while 29.7% of patients sought at least 1 kind of CAM product. Current active disease and Chinese or South Korean nationality over Japanese were independent predictors of CAM use. Chinese doctors were more likely to consider CAM helpful for patients with IBD than were Japanese and South Korean doctors.
Conclusions
In 8.6% and 29.7% of East Asian patients with IBD used CAM services and products, respectively, which does not differ from the prevalence in their Western counterparts. There is a significant gap regarding CAM usage among different Asian countries, not only from the patients’ perspective but also from the physicians’ point of view.

Citations

Citations to this article as recorded by  
  • Use of Complementary and Alternative Medicine by Greek Patients with Inflammatory Bowel Disease
    John Triantafillidis, Aristofanis Gikas, Georgia Kontrarou, Manousos Konstantoulakis, Apostolos Papalois
    Nutrients.2024; 16(21): 3679.     CrossRef
  • Recent Perspective of Lactobacillus in Reducing Oxidative Stress to Prevent Disease
    Tingting Zhao, Haoran Wang, Zhenjiang Liu, Yang Liu, DeJi, Bin Li, Xiaodan Huang
    Antioxidants.2023; 12(3): 769.     CrossRef
  • The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
    Iason Psilopatis, Kleio Vrettou, Constantinos Giaginis, Stamatios Theocharis
    International Journal of Molecular Sciences.2023; 24(10): 8918.     CrossRef
  • 5,002 View
  • 171 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
Inflammatory bowel diseases
The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease
Chan Hyung Lee, Hyuk Yoon, Dong Jun Oh, Jae Min Lee, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
Intest Res 2020;18(1):79-84.   Published online January 30, 2020
DOI: https://doi.org/10.5217/ir.2019.00107
AbstractAbstract PDFPubReaderePub
Background/Aims
Crohn’s disease is associated with altered body composition, such as low muscle mass, which can affect clinical outcomes. However, there are few studies regarding the effect of sarcopenia on prognosis of Crohn’s disease. In this study, we evaluated the body composition at the initial diagnosis of Crohn’s disease and analyzed the clinical meaning of sarcopenia.
Methods
We conducted a retrospective review of medical records of patients who were diagnosed as Crohn’s disease and underwent computed tomography within 3 months after diagnosis. Sarcopenia was defined as an L3 skeletal muscle index (SMI) of < 49 cm2/m2 for men and < 31 cm2/m2 for women. Outcomes such as need for hospitalization, surgery, use of steroids, immunomodulators and biologics were analyzed.
Results
A total of 79 patients (male, 73.4%; mean age, 29.9 years) were included and 40 patients (51%) were diagnosed as sarcopenia. C-reactive protein (CRP) level was correlated with sarcopenia (P= 0.044). Erythrocyte sedimentation rate (ESR) showed a tendency to decrease inversely with SMI (r = –0.320, P= 0.008) and hemoglobin and albumin tended to increase in proportion to SMI (hemoglobin: r = 0.271, P= 0.016 and albumin: r = 0.350, P= 0.002). However, there was no statistically significance in time-to-first-event analysis in aspects of sarcopenia.
Conclusions
Approximately 50% of patients with newly diagnosed as Crohn’s disease had sarcopenia. CRP levels were higher in the sarcopenia group and SMI correlated with ESR, hemoglobin, and albumin. However, none of prognostic values were demonstrated.

Citations

Citations to this article as recorded by  
  • The Relationship Between Intramural Fat Accumulation and Sarcopenia on MR Enterography Exams in Patients with Crohn’s Disease
    Oktay Algin, Yasin Celal Güneş, Rasim Eren Cankurtaran, Seniha Corabay, Oyku Tayfur Yurekli
    RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2025; 197(03): 298.     CrossRef
  • Author’s Reply: Is Sarcopenia More Than Just Low Body Mass?
    Ria Minawala, Adam S Faye
    Inflammatory Bowel Diseases.2025; 31(4): 1191.     CrossRef
  • Evaluating the role of sarcopenia in adverse clinical outcomes for Crohn’s disease patients: a systematic review and meta-analysis
    Othman Saleh, Sakhr Alshwayyat, Muhannad A. L. Hares, Suhaib Shalan, Deya’a Alasmar, Omar Alkurdi, Hamdah Hanifa, Momen Hajali
    International Journal of Colorectal Disease.2025;[Epub]     CrossRef
  • Prevalence and outcome of sarcopenia in patients with inflammatory bowel disease: a follow-up study
    Vikram Dharap, Devendra Desai, Philip Abraham, Tarun Gupta, Pavan Dhoble, Nirad Mehta, Jagdish Modhe
    Intestinal Research.2025;[Epub]     CrossRef
  • New criteria of the Asian working group for sarcopenia: High prevalence of severe sarcopenia in hospitalized patients
    Yeon-Hee Han, MinJeong Kim, Jong Hun Kim, Hwan-Jeong Jeong, Seok Tae Lim
    Medicine.2025; 104(11): e41912.     CrossRef
  • The Prevalence of Sarcopenia in Crohn's Disease Patients and Its Correlation With Disease Activity and Effect on Prognosis
    Srijith Kadavanoor, Susruth Krishnadas P, Naufal Peumpalath, Sunil Kumar K, Sithara K Balagopal
    Cureus.2025;[Epub]     CrossRef
  • Psoas muscle CT radiomics-based machine learning models to predict response to infliximab in patients with Crohn’s disease
    Zhuoyan Chen, Weimin Cai, Yuanhang He, Tianhao Mei, Yuxuan Zhang, Shiyu Li, Yiwen Hong, Yuhao Chen, Huiya Ying, Yuan Zeng, Fujun Yu
    Annals of Medicine.2025;[Epub]     CrossRef
  • Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence
    Pardhu B Neelam, Alka Sharma, Vishal Sharma
    JGH Open.2024;[Epub]     CrossRef
  • The association between hemoglobin level and sarcopenia in Chinese patients with Crohn’s disease
    Nandong Hu, Jingjing Liu, Xifa Gao, Hongye Tang, Jiangchuan Wang, Zicheng Wei, Zhongqiu Wang, Xiaoli Yu, Xiao Chen
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • Ultrasound muscle assessment for sarcopenia detection in inflammatory bowel disease: A prospective study
    Giacomo Mulinacci, Lorena Pirola, Davide Gandola, Davide Ippolito, Chiara Viganò, Alice Laffusa, Camilla Gallo, Pietro Invernizzi, Silvio Danese, Sara Massironi
    United European Gastroenterology Journal.2024; 12(5): 562.     CrossRef
  • Causal associations between autoimmune diseases and sarcopenia-related traits: a bi-directional Mendelian randomization study
    Chunlan Chen, Ying He
    Frontiers in Genetics.2024;[Epub]     CrossRef
  • The relationship between inflammatory bowel disease and sarcopenia-related traits: a bidirectional two-sample mendelian randomization study
    Zhihuang Sun, Guangwei Liu, Jiajia Xu, Xianyu Zhang, Huahua Wei, Guobao Wu, Jian Jiang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Association between sarcopenia and hemoglobin level: a systematic review and meta-analysis
    Hui Wang, Ping Lin
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Micronutrient Deficiency and Muscular Status in Inflammatory Bowel Disease
    Joonhee Han, Hyun Joo Song, Min Sook Kang, Hogyung Jun, Heung Up Kim, Ki Soo Kang, Donghyoun Lee
    Nutrients.2024; 16(21): 3763.     CrossRef
  • Assessment of body composition-related imaging parameters indicative of sarcopenia in Chinese patients with Crohn’s disease: correlation with disease severity and biologic efficacy
    Chen Xie
    American Journal of Translational Research.2024; 16(10): 5427.     CrossRef
  • Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
    Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Digestive Diseases and Sciences.2023; 68(6): 2165.     CrossRef
  • Nutritional Risk and Sarcopenia Features in Patients with Crohn’s Disease: Relation to Body Composition, Physical Performance, Nutritional Questionnaires and Biomarkers
    Konstantinos Papadimitriou, Paraskevi Detopoulou, Konstantinos Soufleris, Gavriela Voulgaridou, Despoina Tsoumana, Panagiotis Ntopromireskou, Constantinos Giaginis, Ioanna P. Chatziprodromidou, Maria Spanoudaki, Sousana K. Papadopoulou
    Nutrients.2023; 15(16): 3615.     CrossRef
  • Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia
    Saskia Inniss, Konstantinos C. Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani, Roser Vega, Ioanna Parisi, Paul Harrow, Edward Seward, Sara McCartney, Stuart Bloom, Andrew M
    Therapeutic Advances in Chronic Disease.2023;[Epub]     CrossRef
  • Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics
    Mauro Grova, Federica Crispino, Marcello Maida, Alessandro Vitello, Sara Renna, Angelo Casà, Lorenzo Tesè, Fabio Salvatore Macaluso, Ambrogio Orlando
    Digestive and Liver Disease.2023; 55(7): 865.     CrossRef
  • The effect of biological agent on body composition in patients with Crohn’s disease
    Eun Jeong Choi, Dong Hoon Baek, Hong Sub Lee, Geun Am Song, Tae Oh Kim, Yong Eun Park, Chang Min Lee, Jong Hoon Lee
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Review article: Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease
    Stephanie L. Gold, Maitreyi Raman, Bruce E. Sands, Ryan Ungaro, João Sabino
    Alimentary Pharmacology & Therapeutics.2023; 57(11): 1216.     CrossRef
  • Association between computed tomography‐assessed sarcopenia and mortality in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis
    Sung Soo Ahn, Yong‐Beom Park, Sang‐Won Lee
    International Journal of Rheumatic Diseases.2023; 26(9): 1704.     CrossRef
  • Imaging-based assessment of body composition in patients with Crohn’s disease: a systematic review
    Wuli Tang, Gang Xie, Danni Wang, Ting Li, Yitao Ren, Junlin Li, Jiaxing Deng, Kang Li
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • Systematic review of sarcopenia in inflammatory bowel disease
    Hala Fatani, Adina Olaru, Rebecca Stevenson, Waad Alharazi, Ayman Jafer, Philip Atherton, Matthew Brook, Gordon Moran
    Clinical Nutrition.2023; 42(8): 1276.     CrossRef
  • Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
    Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
    Nutrients.2023; 15(17): 3824.     CrossRef
  • Magnetic Resonance Imaging Can Be Used to Assess Sarcopenia in Children with Newly Diagnosed Crohn’s Disease
    Paola Blagec, Sila Sara, Ana Tripalo Batoš, Ivana Trivić Mažuranić, Ana Močić Pavić, Zrinjka Mišak, Iva Hojsak
    Nutrients.2023; 15(17): 3838.     CrossRef
  • Key genes of inflammation and Crohn’s disease severity identified via bioinformatics and clinical specimen analysis
    Min Lu, Zhirui Zeng, Yongjian Ling, Qinsong Zhong, Zhiliang Mai, Hua Mao, Qian Wang
    All Life.2023;[Epub]     CrossRef
  • Research progress on the predictive role of sarcopenia in the course and prognosis of inflammatory bowel disease
    Yang Liu, Linglin Tian
    PeerJ.2023; 11: e16421.     CrossRef
  • Characteristics of malnutrition according to Global Leadership Initiative on Malnutrition criteria in non-surgical patients with inflammatory bowel disease
    Shanshan Huang, Yang Niu, Xiaowei Liu, Zhengye Gu, Aiyue Huang, Jiang Wu
    Nutrition.2022; 94: 111514.     CrossRef
  • Nutritional screening and assessment in inflammatory bowel disease
    Arshdeep Singh, Catherine Wall, Arie Levine, Vandana Midha, Ramit Mahajan, Ajit Sood
    Indian Journal of Gastroenterology.2022; 41(1): 5.     CrossRef
  • Association Between Frailty or Sarcopenia and Adverse Outcomes in Inflammatory Bowel Disease: A Systematic Review
    Katherine Bedard, Naheed Rajabali, Puneeta Tandon, Juan G. Abraldes, Farhad Peerani
    Gastro Hep Advances.2022; 1(2): 241.     CrossRef
  • Sarcopenia Is More Prevalent Among Inflammatory Bowel Disease Patients Undergoing Surgery and Predicts Progression to Surgery Among Medically Treated Patients
    James P Campbell, Levi Teigen, Scott Manski, Brian Blumhof, Flavius F Guglielmo, Raina Shivashankar, Eugenia Shmidt
    Inflammatory Bowel Diseases.2022; 28(12): 1844.     CrossRef
  • Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
    Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederi
    The Lancet Gastroenterology & Hepatology.2022; 7(7): 666.     CrossRef
  • Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future
    Adam S. Faye, Tasnin Khan, Sandhya Cautha, Bharati Kochar
    Current Treatment Options in Gastroenterology.2022; 20(3): 250.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?
    Simon Reider, Lukas Binder, Stefan Fürst, Stefan Hatzl, Andreas Blesl
    Cells.2022; 11(21): 3463.     CrossRef
  • Serial Changes in Body Composition and the Association with Disease Activity during Treatment in Patients with Crohn’s Disease
    Ji Young Lee, Kyung Won Kim, Yousun Ko, Chi Hyuk Oh, Bo Hyun Kim, Seong Jin Park, Myung-Won You
    Diagnostics.2022; 12(11): 2804.     CrossRef
  • Low psoas muscle area is associated with postoperative complications in Crohn’s disease
    Yaniv Zager, Saed Khalilieh, Omar Ganaiem, Eli Gorgov, Nir Horesh, Roi Anteby, Uri Kopylov, Harel Jacoby, Yael Dreznik, Assaf Dori, Mordechai Gutman, Avinoam Nevler
    International Journal of Colorectal Disease.2021; 36(3): 543.     CrossRef
  • Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn’s disease
    Gurasis Boparai, Saurabh Kedia, Devasenathipathy Kandasamy, Raju Sharma, Kumble Seetharama Madhusudhan, Nihar Ranjan Dash, Pabitra Sahu, Sujoy Pal, Peush Sahni, Rajesh Panwar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Davesh P. Yadav, Venigalla Pratap Mouli,
    European Journal of Clinical Nutrition.2021; 75(10): 1491.     CrossRef
  • Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview
    Amritpal Dhaliwal, Jonathan I. Quinlan, Kellie Overthrow, Carolyn Greig, Janet M. Lord, Matthew J. Armstrong, Sheldon C. Cooper
    Nutrients.2021; 13(2): 656.     CrossRef
  • Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together
    Francesco Palmese, Rossella Del Toro, Giulia Di Marzio, Pierluigi Cataleta, Maria Giulia Sama, Marco Domenicali
    Nutrients.2021; 13(4): 1378.     CrossRef
  • Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease
    Lewis Steell, Stuart R. Gray, Richard K. Russell, Jonathan MacDonald, John Paul Seenan, Sze Choong Wong, Daniel R. Gaya
    Nutrients.2021; 13(8): 2899.     CrossRef
  • Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance
    Hiroki Nishikawa, Shiro Nakamura, Takako Miyazaki, Kazuki Kakimoto, Shinya Fukunishi, Akira Asai, Shuhei Nishiguchi, Kazuhide Higuchi
    Journal of Clinical Medicine.2021; 10(18): 4214.     CrossRef
  • Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications
    Dorota Skrzypczak, Marzena Skrzypczak-Zielińska, Alicja Ewa Ratajczak, Aleksandra Szymczak-Tomczak, Piotr Eder, Ryszard Słomski, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
    Biomedicines.2021; 9(10): 1301.     CrossRef
  • Adults with Crohn’s disease exhibit elevated gynoid fat and reduced android fat irrespective of disease relapse or remission
    Lisa Dowling, Philip Jakeman, Catherine Norton, Maeve M. Skelly, Hamid Yousuf, Miranda G. Kiernan, Margaret Toomey, Sheila Bowers, Suzanne S. Dunne, J. Calvin Coffey, Colum P. Dunne
    Scientific Reports.2021;[Epub]     CrossRef
  • What Determines Good Rehabilitation Recovery in Stroke Patients with very Severe Disability? A Retrospective Cohort Study
    Shengjie Zhao, Tong Zhang, Bingjie Li, Zhangwei Wu, Jun Zhao
    Journal of Stroke and Cerebrovascular Diseases.2020; 29(10): 105130.     CrossRef
  • Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review
    Hyo Jin An, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Keum Hwa Lee, Seoung Wan Nam, Jae Seok Kim, Jae Won Yang, Jun Young Lee, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Jae Il Shin, Andreas Kronbichler
    International Journal of Molecular Sciences.2020; 21(16): 5678.     CrossRef
  • Diagnosis of malnutrition in patients with gastrointestinal diseases: recent observations from a Global Leadership Initiative on Malnutrition perspective
    Tommy Cederholm, Zeljko Krznaric, Matthias Pirlich
    Current Opinion in Clinical Nutrition & Metabolic Care.2020; 23(5): 361.     CrossRef
  • Incorporating Frailty in the Treatment Program of Elderly Patients with Gastrointestinal Disease
    C. Thompson, S. Taleban
    Current Treatment Options in Gastroenterology.2020; 18(4): 635.     CrossRef
  • 10,409 View
  • 233 Download
  • 49 Web of Science
  • 50 Crossref
Close layer
Editorial
IBD
Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
Hyuk Yoon
Intest Res 2019;17(3):283-284.   Published online July 25, 2019
DOI: https://doi.org/10.5217/ir.2019.00070
PDFPubReaderePub
  • 5,333 View
  • 106 Download
  • 1 Web of Science
Close layer
Original Articles
IBD
The effect of vitamin D administration on inflammatory markers in patients with inflammatory bowel disease
Jae Chang Jun, Hyuk Yoon, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
Intest Res 2019;17(2):210-217.   Published online November 27, 2018
DOI: https://doi.org/10.5217/ir.2018.00081
AbstractAbstract PDFPubReaderePub
Background/Aims
The exact relationship between vitamin D deficiency and inflammatory bowel disease (IBD) remains unclear. We evaluated the effect of vitamin D3 administration on inflammatory responses and disease severity in patients with IBD.
Methods
We investigated the serum 25-hydroxyvitamin D3 [25-(OH)D] and C-reactive protein (CRP) levels and the partial Mayo score (PMS) in patients with IBD. Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration.
Results
In 88 patients with Crohn’s disease (CD), a negative correlation was found between serum vitamin D and CRP. In 178 patients with ulcerative colitis (UC), serum vitamin D showed no association with CRP or PMS. Serum vitamin D increased from 11.08±3.63 to 22.69±6.11 ng/mL in 29 patients with CD and from 11.45±4.10 to 24.20±6.61 ng/mL in 41 patients with UC who received vitamin D3 treatment (P<0.001 and P<0.001, respectively). In patients with CD, median ΔCRP was –0.24 in the normalized vitamin D group and –0.11 in the non-normalized group (P=0.308). In patients with UC, median ΔCRP was −0.01 in the normalized vitamin D group and 0.06 in the non-normalized group (P=0.359).
Conclusions
Although a negative correlation was found between serum vitamin D and CRP levels in patients with CD, administration of vitamin D did not improve the CRP level in patients with CD. In patients with UC, serum vitamin D level was unrelated to CRP or PMS.

Citations

Citations to this article as recorded by  
  • The use of vitamin D for patients with inflammatory bowel diseases
    Júlia Novaes Matias, Vinícius Marinho Lima, Giovanna Soares Nutels, Lucas Fornari Laurindo, Sandra Maria Barbalho, Ricardo de Alvares Goulart, Adriano Cressoni Araújo, Rodrigo Buzinaro Suzuki, Elen Landgraf Guiguer
    International Journal for Vitamin and Nutrition Research.2024; 94(1): 54.     CrossRef
  • The effect of vitamin D serum levels on the values of C-reactive protein and fecal calprotectin in patients with ulcerative colitis in clinical remission
    Zarko Krnetic, Tijana Icin, Zeljka Savic, Olgica Latinovic Bosnjak, Vladimir Vracaric, Dimitrije Damjanov, Tatiana Jocic, Radoslav Pejin, Nebojsa Janjic
    Vojnosanitetski pregled.2024; 81(10): 619.     CrossRef
  • Low Vitamin K and Vitamin D Dietary Intake in Patients with Inflammatory Bowel Diseases
    Filippo Vernia, Giorgia Burrelli Scotti, Noemi Sara Bertetti, Giuseppe Donato, Stefano Necozione, Piero Vernia, Nadia Pallotta
    Nutrients.2023; 15(7): 1678.     CrossRef
  • High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
    Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
    Clinical Gastroenterology and Hepatology.2022; 20(5): e1022.     CrossRef
  • High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection
    Sang Hoon Lee, Han-Ki Park, Chang Don Kang, Dae Hee Choi, Sung Chul Park, Jin Myung Park, Seung-Joo Nam, Gi Bong Chae, Kyoung yul Lee, Hyunseok Cho, Sung Joon Lee
    Frontiers in Cellular and Infection Microbiology.2022;[Epub]     CrossRef
  • Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease
    Nam Seok Ham, Sung Wook Hwang, Eun Hye Oh, Jeongseok Kim, Ho-Su Lee, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Digestive Diseases and Sciences.2021; 66(2): 587.     CrossRef
  • Effects of a Single Oral Megadose of Vitamin D3 on Inflammation and Oxidative Stress Markers in Overweight and Obese Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Laine de Carvalho Guerra Pessoa Mamede, Rafaela Lira Formiga Cavalcanti de Lima, Alexandre Sérgio Silva, João Carlos Lima Rodrigues Pita, Nadjeanny Ingrid Galdino Gomes, Elisama Araújo de Sena, Rhayra Priscila Moraes Nobrega, João Otávio Scarano Alcântara
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 525.     CrossRef
  • The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency
    Anna Zielińska, Aleksandra Sobolewska-Włodarczyk, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Jakub Fichna, Maciej Sałaga
    Pharmaceuticals.2021; 14(3): 284.     CrossRef
  • The effects of consuming a low-fat yogurt fortified with nano encapsulated vitamin D on serum pro-oxidant-antioxidant balance (PAB) in adults with metabolic syndrome; a randomized control trial
    Niloofar Taghizadeh, Payam Sharifan, Mansoureh Sadat Ekhteraee Toosi, Fatemeh Najar Sedgh Doust, Susan Darroudi, Asma Afshari, Mitra Rezaie, Mohamad Safarian, Hassan Vatanparast, Saeed Eslami, Hamideh Ghazizadeh, Zahra Khorasanchi, Mohammad Bagherniya, Go
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(6): 102332.     CrossRef
  • Vitamin D and inflammatory bowel disease: what do we know so far?
    Antonio María Caballero Mateos, Raúl Vicente Olmedo-Martín, Amparo Roa-Colomo, María del Mar Díaz Alcázar, Manuel Valenzuela Barranco
    Revista Española de Enfermedades Digestivas.2020;[Epub]     CrossRef
  • Inflammatory Bowel Disease and Vitamin D
    Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon
    The Korean Journal of Gastroenterology.2020; 76(6): 275.     CrossRef
  • Vitamin D in Inflammatory Bowel Disease: Biological, Clinical and Therapeutic Aspects
    Raúl Vicente Olmedo-Martín, Inmaculada González-Molero, Gabriel Olveira, Víctor Amo-Trillo, Miguel Jiménez-Pérez
    Current Drug Metabolism.2019; 20(5): 390.     CrossRef
  • Intraluminal Farnesol and Farnesal in the Mealworm's Alimentary Canal: An Unusual Storage Site Uncovering Hidden Eukaryote Ca2+-Homeostasis-Dependent “Golgicrine” Activities
    Arnold De Loof, Liliane Schoofs
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • 8,004 View
  • 222 Download
  • 17 Web of Science
  • 13 Crossref
Close layer
Colorectal neoplasia
Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer
In Sub Jung, Cheol Min Shin, Sung Jae Park, Young Soo Park, Hyuk Yoon, Hyun Jin Jo, Nayoung Kim, Dong Ho Lee
Intest Res 2019;17(3):404-412.   Published online November 12, 2018
DOI: https://doi.org/10.5217/ir.2018.00072
AbstractAbstract PDFPubReaderePub
Background/Aims
To examine whether visceral adiposity serves as a risk factor for colorectal cancer (CRC) and colorectal adenomas.
Methods
Two hundred healthy subjects, 200 patients with colorectal adenoma, and 151 patients with CRC (46 with early-stage and 105 with advanced-stage cancers) were enrolled at a tertiary referral hospital. All subjects underwent colonoscopy, and had laboratory data, and computed tomography (CT) scan available for abdominal fat measurement. An abdominal CT scan taken 1 to 4 years (mean interval, 20.6 months) before the diagnosis of CRC was also available in the 42 CRC patients.
Results
The mean areas of visceral adipose tissue (VAT) areas in the control, adenoma, early- and advanced-stage CRC groups were 94.6, 116.8, 110.4, and 99.7 cm2 , respectively (P<0.001). The risk of adenoma positively correlated with VAT area and the visceral-to-total fat ratio (P for trend <0.01), but the risk of CRC did not (P>0.05). The risk of both adenoma and CRC positively correlated with fasting plasma glucose levels (P for trend <0.05). In patients with early-stage cancer (n=17), VAT area decreased when the CT scan at diagnosis was compared with that taken before the diagnosis of CRC, but superficial adipose tissue area did not, so visceral-to-total fat ratio significantly decreased (46.6% vs. 50.7%, respectively, P=0.018)
Conclusions
VAT area is related to the risk of colorectal adenoma. However, VAT decreases from the early stages of CRC. Impaired fasting glucose has a role in colorectal carcinogenesis.

Citations

Citations to this article as recorded by  
  • The role of Adiponectin and Leptin in Colorectal Cancer and Adenoma: a systematic review and meta-analysis
    Iman Elahi Vahed, Mahsa Moshgelgosha, Abdolmajid Kor, Mona Minadi, Faezeh Ebrahimi, Aylar Azhdarian, Mobina Arjmandi, Aida Alamdar, Maede Zare, Niloufar Shabani, Hossein Soltaninejad, Mohammad Rahmanian
    BMC Cancer.2025;[Epub]     CrossRef
  • Change in abdominal obesity after colon cancer surgery – effects of left-sided and right-sided colonic resection
    Younes Kays Mohammed Ali, Troels Gammeltoft Dolin, Janus Damm Nybing, Jakob Lykke, Frederik Hvid Linden, Erik Høgh-Schmidt, Thorkild I. A. Sørensen, Jesper Frank Christensen, Yousef J. W. Nielsen, Jim Stenfatt Larsen, Sten Madsbad, Julia Sidenius Johansen
    International Journal of Obesity.2024; 48(4): 533.     CrossRef
  • Research Progress on the Correlation between Metabolic Syndrome and Colorectal Polyps
    欣然 王
    Advances in Clinical Medicine.2024; 14(03): 1733.     CrossRef
  • MAFLD with central obesity is associated with increased risk of colorectal adenoma and high-risk adenoma
    Jingfang Xiong, Yijun Wu, Dongya Chen, Zhaolin Zhang, Yihui Liu, Jiandong Luo, Hong Xu
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Association between Atherosclerosis and High-Risk Colorectal Adenomas based on Cardio-Ankle Vascular Index and Ankle-Brachial Index
    Jung Ho Lee, Hyunseok Cho, Sang Hoon Lee, Sung Joon Lee, Chang Don Kang, Dae Hee Choi, Jin Myung Park, Seung-Joo Nam, Tae Suk Kim, Ji Hyun Kim, Sung Chul Park
    The Korean Journal of Gastroenterology.2024; 83(4): 143.     CrossRef
  • Hot Spots and Trends in the Relationship between Cancer and Obesity: A Systematic Review and Knowledge Graph Analysis
    Le Gao, Tian Yang, Ziru Xue, Chak Kwan Dickson Chan
    Life.2023; 13(2): 337.     CrossRef
  • Abdominal fat and muscle distributions in different stages of colorectal cancer
    Jun Han, Xinyang Liu, Min Tang, Fan Yang, Zuoyou Ding, Guohao Wu
    BMC Cancer.2023;[Epub]     CrossRef
  • Arterial stiffness is associated with high-risk colorectal adenomas and serrated lesions: A cross-sectional study in a Taiwanese population
    Hung-Yu Chen, Wen-Huang Lee, Hung-Lung Hsu, Yu-Tsung Chou, Fei-Lin Su, I-Hsuan Wu, Ting-Hsing Chao
    Journal of Cardiology.2022; 80(2): 139.     CrossRef
  • Relationship between BMI, CT-derived body composition and colorectal neoplasia in a bowel screening population
    Domenic G. Di Rollo, Josh McGovern, Christopher Morton, Gillian Miller, Ross Dolan, Paul G. Horgan, Donald C. McMillan, David Mansouri
    Scottish Medical Journal.2022; 67(3): 93.     CrossRef
  • Review article: obesity and colorectal cancer
    Marc Bardou, Alexia Rouland, Myriam Martel, Romaric Loffroy, Alan N. Barkun, Nicolas Chapelle
    Alimentary Pharmacology & Therapeutics.2022; 56(3): 407.     CrossRef
  • The Association of Waist Circumference with the Prevalence and Survival of Digestive Tract Cancer in US Adults: A Population Study Based on Machine Learning Methods
    Xingyu Jiang, Qi Liang, Huanhuan Xu, Shouyong Gu, Lingxiang Liu, Jincheng Wang
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Obesity Is Not an Independent Predictor of Necrotizing Soft Tissue Infection Outcomes
    Hannah Zhao-Fleming, Mhd Hasan Almekdash, Elizabeth Cook, Armand Northcut, Diana Mitchell, Kendra Rumbaugh, Sharmila Dissanaike
    Surgical Infections.2021; 22(2): 187.     CrossRef
  • Optimization of the surveillance strategy in patients with colorectal adenomas: A combination of clinical parameters and index colonoscopy findings
    Chan Hyuk Park, Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2021; 36(4): 974.     CrossRef
  • Obesity, sleep apnea, and cancer
    Isaac Almendros, Miguel A. Martinez-Garcia, Ramon Farré, David Gozal
    International Journal of Obesity.2020; 44(8): 1653.     CrossRef
  • Opportunistic use of radiological measures of visceral adiposity for assessment of risk of colorectal adenoma
    Zi Qin Ng, Ruwan Wijesuriya, Philip Misur, Jih Huei Tan, Kyaw Soe Moe, Mary Theophilus
    ANZ Journal of Surgery.2020; 90(11): 2298.     CrossRef
  • Changes in Abdominal Obesity Affect the Risk of Metachronous Advanced Colorectal Neoplasia Development after Polypectomy
    Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Yonsei Medical Journal.2020; 61(7): 579.     CrossRef
  • 40,821 View
  • 185 Download
  • 16 Web of Science
  • 16 Crossref
Close layer
Colorectal neoplasia
Clinical features and outcomes in spontaneous intramural small bowel hematoma: cohort study and literature review
Eun Ae Kang, Seung Jun Han, Jaeyoung Chun, Hyun Jung Lee, Hyunsoo Chung, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyun Chae Jung
Intest Res 2019;17(1):135-143.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00085
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Spontaneous intramural small bowel hematoma (SISBH) is an extremely rare complication of anticoagulant or antiplatelet therapy. We assessed the clinical characteristics and outcomes of patients with SISBH according to the anatomical location of the hematoma.
Methods
From January 2003 to February 2016, medical records for all patients hospitalized for SISBH at 2 tertiary referral hospitals were retrospectively reviewed. The primary outcome was requirement for surgery.
Results
A total of 37 patients were enrolled. The mean age was 74.1 years. Among them, 33 patients (89.2%) were taking anticoagulant and/or antiplatelet agents. Duodenal intramural hematoma was detected in 4 patients (10.8%), jejunal in 16 (43.2%), and ileal in 17 (45.9%). Compared to jejunal and ileal involvement, duodenal intramural hematoma was significantly associated with high Charlson comorbidity index and low levels of white blood cells, hemoglobin, and platelets in the blood. SISBH in the duodenum was related to thrombocytopenia in 3 patients following systemic chemotherapy for malignancy. All patients with SISBH showed clinical improvement with conservative therapy. Mean length of hospital stay was 9.35 days. Independent predictors of a hospital stay of more than 7 days were body weight less than 60 kg (odds ratio [OR], 12.213; 95% confidence interval [CI], 1.755–84.998; P=0.011) and a history of cerebrovascular accidents (OR, 6.667; 95% CI, 1.121–39.650; P=0.037).
Conclusions
Compared to jejunal and ileal involvement, thrombocytopenia may result in spontaneous duodenal intramural hematoma among patients who are treated with systemic chemotherapy for malignancies. Patients with SISBH have excellent clinical outcomes with conservative therapy regardless of the anatomical location of the hematoma.

Citations

Citations to this article as recorded by  
  • Drug-Induced Spontaneous Intramural Hematoma of the Gastrointestinal Tract: A Real-World Pharmacovigilance Analysis
    Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou
    Journal of Cardiovascular Pharmacology.2025; 85(4): 297.     CrossRef
  • Idiopathic Duodenal Hematoma: A Case Report and Literature Review
    Ebtesam Al-Najjar, Abdullah Esmail, Bayan Khasawneh, Saifudeen Abdelrahim, Maen Abdelrahim
    Reports.2025; 8(2): 73.     CrossRef
  • A Case of Direct-Acting Oral Anticoagulant-Induced Intramural Colon Hematoma Successfully Treated by Laparoscopic Surgery
    Daisuke Tomita, Shigeo Toda, Ryo Miyazaki, Shuichiro Matoba, Hiroya Kuroyanagi
    Cureus.2024;[Epub]     CrossRef
  • Spontaneous Intramural Small Bowel Hematoma in an Elderly Man with Multiple Myeloma
    Sigrid L. Williamson, Aishwarya Suresh, Adrian Ong
    The American Surgeon™.2023; 89(6): 2816.     CrossRef
  • Intramural duodenal hematoma: diagnosis and management of a rare entity
    Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
    Cirugía Española (English Edition).2023; 101(7): 515.     CrossRef
  • Hematoma intramural duodenal: diagnóstico y manejo de una entidad infrecuente
    Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
    Cirugía Española.2023; 101(7): 515.     CrossRef
  • Jejunal intramural haematoma in a captive African lion (Panthera leo)
    Richelle G. Butcher, Baukje Lenting, Alison S. Clarke, Kelly Buckle, Cristina Gans
    Veterinary Record Case Reports.2023;[Epub]     CrossRef
  • Spontaneous Duodenal Hematoma: A Rare Complication of Triple Antithrombotic Therapy Case Report
    Mazin N Habhab, Asad J Torabi, Julie M Clary, George E Revtyak
    Future Cardiology.2023; 19(2): 71.     CrossRef
  • Intestinal Spontaneous Intramural Hematoma Secondary to Anticoagulation Therapy: A Case Report
    Karim El Aidaoui, Wahib Lahlou, Abderrahim Bourial, Nawal Bouknani, Chafik El Kettani
    Cureus.2023;[Epub]     CrossRef
  • Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B
    Wei-Jung Teng, Ching-Huei Kung, Mei-Mei Cheng, Jia-Ruey Tsai, Chia-Yau Chang
    Journal of Clinical Medicine.2023; 12(9): 3093.     CrossRef
  • Endoscopic management of intramural spontaneous duodenal hematoma: A case report
    Giorgio Valerii, Vittorio Maria Ormando, Carlo Cellini, Luca Sacco, Carmelo Barbera
    World Journal of Gastroenterology.2022; 28(20): 2243.     CrossRef
  • Warfarin-induced spontaneous intramural small bowel hematoma presenting as an acute abdomen: A case report
    Ding-Han Chen, Khay-Seng Soh, Ying-Tso Wang, Te-Chun Shen
    Medicine.2022; 101(35): e30335.     CrossRef
  • Spontaneous duodenal haematoma in a patient taking rivaroxaban
    Rebeca de Barros Lopes, Finn McLennan Battleday, Toby Calvert, Rob Gwynne‐Jones, Rebecca Thomas
    ANZ Journal of Surgery.2021;[Epub]     CrossRef
  • SPONTANEOUS INTRAMURAL SMALL-BOWEL HEMATOMA: A CAUSE OF ACUTE ABDOMEN IN ANTICOAGULATED PATIENTS
    Sergio Gil Rojas, Luis Miguel Estela Villa, Elsa María Jiménez Vicente
    Revista Española de Enfermedades Digestivas.2021;[Epub]     CrossRef
  • Small Bowel Obstruction
    Allison A. Aka, Jesse P. Wright, Teresa DeBeche-Adams
    Clinics in Colon and Rectal Surgery.2021; 34(04): 219.     CrossRef
  • Double Trouble: Spontaneous Duodenal Hematoma of Pancreatic Origin
    Luísa Martins Figueiredo, David Valadas Horta, Jorge A. Reis
    GE - Portuguese Journal of Gastroenterology.2019; 26(6): 458.     CrossRef
  • 28,689 View
  • 256 Download
  • 19 Web of Science
  • 16 Crossref
Close layer
Endoscopy
Clinical outcomes of surveillance colonoscopy for patients with sessile serrated adenoma
Sung Jae Park, Hyuk Yoon, In Sub Jung, Cheol Min Shin, Young Soo Park, Na Young Kim, Dong Ho Lee
Intest Res 2018;16(1):134-141.   Published online January 18, 2018
DOI: https://doi.org/10.5217/ir.2018.16.1.134
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Sessile serrated adenomas (SSAs) are known to be precursors of colorectal cancer (CRC). The proper interval of follow-up colonoscopy for SSAs is still being debated. We sought to determine the proper interval of colonoscopy surveillance in patients diagnosed with SSAs in South Korea.

Methods

We retrospectively reviewed the medical records of patients diagnosed with SSAs who received 1 or more follow-up colonoscopies. The information reviewed included patient baseline characteristics, SSA characteristics, and colonoscopy information.

Results

From January 2007 to December 2011, 152 SSAs and 8 synchronous adenocarcinomas were identified in 138 patients. The mean age of the patients was 62.2 years and 60.1% patients were men. SSAs were located in the right colon (i.e., from the cecum to the hepatic flexure) in 68.4% patients. At the first follow-up, 27 SSAs were identified in 138 patients (right colon, 66.7%). At the second follow-up, 6 SSAs were identified in 65 patients (right colon, 66.7%). At the 3rd and 4th follow-up, 21 and 11 patients underwent colonoscopy, respectively, and no SSAs were detected. The total mean follow-up duration was 33.9 months. The mean size of SSAs was 8.1±5.0 mm. SSAs were most commonly found in the right colon (126/185, 68.1%). During annual follow-up colonoscopy surveillance, no cancer was detected.

Conclusions

Annual colonoscopy surveillance is not necessary for identifying new CRCs in all patients diagnosed with SSAs. In addition, the right colon should be examined more carefully because SSAs occur more frequently in the right colon during initial and follow-up colonoscopies.

Citations

Citations to this article as recorded by  
  • Prevalence and Characteristics of Colorectal Serrated Polyps
    Soo-Young Na
    Journal of Digestive Cancer Research.2025; 13(1): 47.     CrossRef
  • Endoscopic Diagnosis, Treatment, and Follow-up of Serrated Polyps
    Duk Hwan Kim
    Journal of Digestive Cancer Research.2023; 11(1): 30.     CrossRef
  • Features associated with high‐risk sessile serrated polyps at index and follow‐up colonoscopy
    Shahzaib Anwar, Charles Cock, Joanne Young, Graeme P Young, Rosie Meng, Kalindra Simpson, Michelle Coats, Junming Huang, Peter Bampton, Robert Fraser, Erin L Symonds
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1620.     CrossRef
  • Descriptive epidemiological study of South African colorectal cancer patients at a Johannesburg Hospital Academic institution
    Michelle McCabe, Yvonne Perner, Rindidzani Magobo, Sheefa Mirza, Clement Penny
    JGH Open.2020; 4(3): 360.     CrossRef
  • Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia
    Xinwei Hua, Polly A. Newcomb, Jessica Chubak, Rachel C. Malen, Rebecca Ziebell, Aruna Kamineni, Lee-Ching Zhu, Melissa P. Upton, Michelle A. Wurscher, Sushma S. Thomas, Hana Newman, Sheetal Hardikar, Andrea N. Burnett-Hartman
    Cancer Causes & Control.2020; 31(7): 631.     CrossRef
  • The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia
    Andrea N. Burnett-Hartman, Jessica Chubak, Xinwei Hua, Rebecca Ziebell, Aruna Kamineni, Lee-Ching Zhu, Melissa P. Upton, Rachel C. Malen, Sheetal Hardikar, Polly A. Newcomb
    Cancer Causes & Control.2019; 30(9): 979.     CrossRef
  • Surveillance colonoscopy in patients with sessile serrated adenoma
    Ji Hyung Nam, Hyoun Woo Kang
    Intestinal Research.2018; 16(3): 502.     CrossRef
  • 13,570 View
  • 70 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Review
Second Korean guidelines for the management of Crohn's disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
Intest Res 2017;15(1):38-67.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.38
AbstractAbstract PDFSupplementary MaterialPubReaderePub

Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.

Citations

Citations to this article as recorded by  
  • Anti–Tumor Necrosis Factor Therapy and the Risk of Gestational Diabetes in Pregnant Women With Inflammatory Bowel Disease
    Yongtai Cho, Eun-Young Choi, Ahhyung Choi, Jung Yeol Han, Byong Duk Ye, Ju Hwan Kim, Ju-Young Shin
    American Journal of Gastroenterology.2025; 120(1): 241.     CrossRef
  • Appraisal of current surgical guidelines for inflammatory bowel disease using the AGREE‐S instrument: A scoping review
    Zarnigar Mussarat Khan, Camille Ball, Dalha Saeed, Grace Tai, Shaneil Chandran, Abhishek Vashista, Simon Davey, Matthew James Lee, Steven R. Brown, Daniel Hind, Adele Elizabeth Sayers
    Colorectal Disease.2025;[Epub]     CrossRef
  • Comparison of 1‐Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study
    Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi‐Thu Nguyen, Nga Thi Dinh, Lien Thi‐Phuong Nguyen, Khien Van Vu, Minh Cuong Duong
    JGH Open.2025;[Epub]     CrossRef
  • Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn’s Disease: A Multicenter Observational Study
    Jihye Park, Jaeyoung Chun, Soo Jung Park, Jae Jun Park, Tae Il Kim, Hyuk Yoon, Jae Hee Cheon
    Digestive Diseases and Sciences.2024; 69(3): 901.     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • Mobile monitoring system detects the disease activity pattern and shows the association with clinical outcomes in patients with newly diagnosed Crohn’s disease
    Yoo Jin Lee, Sang Gyu Kwak, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Yun Jin Chung, Byung Ik Jang, Kyeong Ok Kim, Jeongseok Kim, Hyeong Ho Jo, Eun Young Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
    Won Moon, Jae Jun Park
    The Korean Journal of Gastroenterology.2024; 83(6): 233.     CrossRef
  • Modern treatment of perianal fistulas following Crohn’s disease
    A.L. Bejanyan, A.A. Bumbazhai, K.N. Petrenko, A.A. Sumbaev, A.V. Matinyan, I.I. Eremin
    Regenerative biotechnologies, preventive, digital and predictive medicine.2024; 1(2): 49.     CrossRef
  • Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
    Sang Un Kim, Hyun Seok Lee
    The Korean Journal of Gastroenterology.2024; 84(2): 35.     CrossRef
  • Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
    Joo Kyung Kim, Jae Hee Cheon
    Journal of Yeungnam Medical Science.2023; 40(1): 37.     CrossRef
  • Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
    Gi Hyeon Seo, Sung Hoon Jung
    Journal of Clinical Medicine.2023; 12(6): 2397.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Can balloon-assisted enteroscopy predict disease outcomes in patients with small-bowel Crohn’s disease?
    Ji Eun Na, Sung Noh Hong, Ji Eun Kim, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
    Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae-Seop Shin, Yoon-Keun Kim, Jin Ran Kim, Yoo Na Lee, Young-Ho Kim, Joo Sung Kim, Jae Hee Cheon
    Scientific Reports.2022;[Epub]     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
    Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
    Gut and Liver.2022; 16(6): 907.     CrossRef
  • Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
    Jae Hee Cheon
    Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn’s Disease Patients
    Pyeong Hwa Kim, Seo Hee Kim, Young Ah Cho, Hee Mang Yoon, Jin Seong Lee, Ah Young Jung, Seak Hee Oh, Dae Yeon Kim, Jung-Man Namgoong, Kyung Mo Kim
    Journal of Crohn's and Colitis.2021; 15(7): 1152.     CrossRef
  • Predictors of reoperation for perianal fistula in Crohn's disease
    Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung
    Journal of Digestive Diseases.2021; 22(6): 334.     CrossRef
  • Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
    Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
    Intestinal Research.2020; 18(1): 85.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease
    Min Seob Kwak, Jae Myung Cha, Ji Hyun Ahn, Min Kyu Chae, Sara Jeong, Hun Hee Lee
    Medicine.2020; 99(10): e18925.     CrossRef
  • Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
    Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
    JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
  • Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study
    Han H. Lee, Jung Min Bae, Bo‐In Lee, Kang‐Moon Lee, Jeong H. Wie, Jin S. Kim, Young‐Seok Cho, Sung‐Ae Jung, Sang W. Kim, Hwang Choi, Myung‐Gyu Choi
    Alimentary Pharmacology & Therapeutics.2020; 51(9): 861.     CrossRef
  • Effects of various genetic polymorphisms on thiopurine treatment‐associated outcomes for Korean patients with Crohn's disease
    Rihwa Choi, Mi‐Na Lee, Kyunga Kim, Sun‐Young Baek, Tae Jun Kim, Sung Noh Hong, Young‐Ho Kim, Soo‐Youn Lee
    British Journal of Clinical Pharmacology.2020; 86(11): 2302.     CrossRef
  • Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
    Jae Jun Park
    Journal of Rheumatic Diseases.2020; 27(3): 128.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1166.     CrossRef
  • A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
    Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn
    Clinical Drug Investigation.2019; 39(7): 625.     CrossRef
  • Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
    Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
    International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
  • Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics
    Ji Young Chang, Jae Hee Cheon
    Digestive Diseases and Sciences.2019; 64(9): 2395.     CrossRef
  • Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
    Jung Eun Ha, Eun Jin Jang, Seul Gi Im, Hyun Soon Sohn
    Korean Journal of Clinical Pharmacy.2019; 29(2): 79.     CrossRef
  • Can Umbilical Cord Mesenchymal Stem Cells Treatment Be a Hope for Patients with Refractory Crohn's Disease?
    Younjoo Kim
    Gut and Liver.2018; 12(1): 5.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
    You Sun Kim
    The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population‐based cohort study
    J. M. Bae, H. H. Lee, B.‐I. Lee, K.‐M. Lee, S. H. Eun, M.‐L. Cho, J. S. Kim, J. M. Park, Y.‐S. Cho, I. S. Lee, S. W. Kim, H. Choi, M.‐G. Choi
    Alimentary Pharmacology & Therapeutics.2018; 48(2): 196.     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
    Sehyung Pak, Sung Wook Hwang, In Kyong Shim, Sang Mun Bae, Yeon- Mi Ryu, Han-Byul Kim, Eun-ju Do, Hye-Nam Son, Eun-ji Choi, Sun-ha Park, Sang-Yeob Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Nobuo Kanai, Masanori Maeda, Teruo Okano, Dong-Hoon Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
    Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
    Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280.     CrossRef
  • Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
    Jong Pil Im
    Intestinal Research.2017; 15(2): 147.     CrossRef
  • Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease
    Taku Kobayashi, Asahi Hishida, Hiroki Tanaka, Yoichiro Nuki, Shigeki Bamba, Akihiro Yamada, Toshimitsu Fujii, Shinichiro Shinzaki, Yoko Yokoyama, Atsushi Yoshida, Keiji Ozeki, Shinya Ashizuka, Noriko Kamata, Sohachi Nanjo, Kazuki Kakimoto, Misaki Nakamura
    Inflammatory Bowel Diseases.2017; 23(12): 2245.     CrossRef
  • Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
    Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
    Intestinal Research.2017; 15(4): 524.     CrossRef
  • Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
    Dai Jung, Sunghee Lee, Insook Jeong, Seak Hee Oh, Kyung Mo Kim
    Pediatric Gastroenterology, Hepatology & Nutrition.2017; 20(4): 236.     CrossRef
  • 12,657 View
  • 165 Download
  • 42 Web of Science
  • 46 Crossref
Close layer
Case Report
A Case of Immune Thrombocytopenic Purpura Associated with Preexisting Ulcerative Colitis Treated with Colectomy and Splenectomy
Jee Hye Kwon, Changhyun Lee, Ji Min Choi, Yoo Min Han, Young Hoon Choi, June Young Lee, Hyuk Yoon, Jaeyoung Chun, Kyu Joo Park, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim, Hyun Chae Jung
Intest Res 2013;11(4):310-316.   Published online October 30, 2013
DOI: https://doi.org/10.5217/ir.2013.11.4.310
AbstractAbstract PDF
Ulcerative colitis is a chronic inflammatory bowel disease of unknown etiology, associated with extraintestinal manifestations, including the rarely reported immune thrombocytopenic purpura. Here, we present a case of immune thrombocytopenic purpura associated with preexisting ulcerative colitis. The patient was diagnosed with ulcerative colitis 13 years ago. Two years after diagnosis, he presented with hematochezia and active ulcerative colitis. Despite steroid use, the platelet count gradually decreased to 21,000/mm3. Hematochezia and the platelet count recovered after the administration of cyclosporine, and ulcerative colitis was in near complete remission for 11 years. However, the patient was re-admitted for hematochezia and thrombocytopenia persisting over a month. Medical management including increased doses of steroids in combination with cyclosporin failed to control hematochezia and thrombocytopenia. Immune thrombocytopenic purpura was suspected on the basis of normocellular marrow with a normal number of megakaryocytes. To treat uncontrolled colitis and steroid-refractory thrombocytopenia, total proctocolectomy with ileal pouch-anal anastomosis and splenectomy were performed. The patient was followed up for 10 months after surgery and was found to be in good health with a normal platelet count. Therefore, colectomy alone or in combination with splenectomy should be considered in cases of life-threatening ulcerative colitis complicated with steroid-refractory immune thrombocytopenic purpura. (Intest Res 2013;11:310-316)

Citations

Citations to this article as recorded by  
  • Resolved Hypereosinophilic Syndrome and Immune Thrombocytopenic Purpura in Ulcerative Colitis Patients Post Colectomy: A Case Series and Literature Review
    Ahmed Hussein Subki, Manal Ismail Bokhary, Sultan Abdulrahman Alandijani, Mohannad Abdulrahman Aljehani, Ahmed Wasel Alharbi, May Alzahrani, Saud Suliman Almuhammadi, Bassim Tahseen Albeirouti, Mohamed Abdulmajid Abduljabar, Silvio Danese
    Journal of Inflammation Research.2022; Volume 15: 6373.     CrossRef
  • A Case of Immune Thrombocytopenic Purpura Accompanying Ulcerative Colitis
    Hyun Tae Kim, Tae Oh Kim, Hyung Jun Kim, Soon Il Lee, Gi Jung Jeon, Eun Ji Lee, Seunghyun Park, Taehoon No
    The Korean Journal of Gastroenterology.2014; 64(4): 234.     CrossRef
  • 2,975 View
  • 15 Download
  • 2 Crossref
Close layer
Original Article
Comparison of Bowel Preparation Depending on Completion Time of Polyethylene Glycol Ingestion and Start Time of Colonoscopy
Jang Hyuk Yoon, Dong Il Park, Jeong Eun Shin, Seong Eun Kim, Sung Ae Jung, Suck Ho Lee, Dong Kyung Chang, Chang Soo Eun, Dong Soo Han, Hyun Soo Kim, Seun Ja Park, Il Hyun Baek, Bora Keum, Yoon Tae Jeen
Intest Res 2010;8(1):24-29.   Published online June 30, 2010
DOI: https://doi.org/10.5217/ir.2010.8.1.24
AbstractAbstract PDF
Background/Aims
Polyethylene glycol (PEG) solution is the most widely used bowel preparation agent for colonoscopy because of its safety and efficacy in colon cleansing. It has been hypothesized that the timing of colon preparation may influence the quality of colon cleansing, and therefore affect the diagnostic yield of colonoscopy. The aim of this study was to determine the optimal interval of time between complete ingestion of PEG and performing colonoscopy. Methods: We prospectively enrolled 1,355 patients who had undergone a PEG-based bowel preparation on the day of colonoscopy in 11 tertiary hospitals in Korea between March 2008 and February 2009. All colonoscopies were performed in the afternoon. The start time of PEG ingestion, completion time of PEG ingestion, dose of PEG ingested, start time of colonoscopy, and the quality of bowel cleansing were recorded. Results: There was no difference of cleansing quality of bowel preparation between three groups of less than 7 hours of elapsed time (2≤ and <3 hours, 3≤ and <5 hours, 5≤ and <7 hours). However, group of more than 7 hours of elapsed time presented poor cleansing quality than others (P<0.01). Conclusions: If >7 hours elapses after ingestion of PEG, the quality of bowel preparation is poor. Therefore, depending on the time colonoscopy is scheduled, the start time of PEG ingestion may need to be adjusted. (Intest Res 2010;8:24-29)

Citations

Citations to this article as recorded by  
  • The optimal bowel preparation intervals before colonoscopy: A randomized study comparing polyethylene glycol and low-volume solutions
    Vladimir Kojecky, Jan Matous, Radan Keil, Milan Dastych, Zdena Zadorova, Michal Varga, Radek Kroupa, Jiri Dolina, Miroslav Misurec, Ales Hep, Martin Griva
    Digestive and Liver Disease.2018; 50(3): 271.     CrossRef
  • Comparative Study on Bowel Preparation Efficacy of Ascorbic Acid Containing Polyethylene Glycol by Adding Either Simethicone or 1 L of Water in Health Medical Examination Patients: A Prospective Randomized Controlled Study
    Se Hwan Yeo, Jae Hoon Kwak, Yeo Un Kim, Tae Ho Kwon, Jeong Bae Park, Jun Hyung Park, Yong Kook Lee, Yun Jeong Lim, Chang Heon Yang
    The Korean Journal of Gastroenterology.2016; 67(4): 189.     CrossRef
  • Randomized Controlled Trial of Sodium Phosphate Tablets versus 2 L Polyethylene Glycol Solution for Bowel Cleansing prior to Colonoscopy
    Yun Ho Lee, Seong Yeon Jeong, You Sun Kim, Hye Jin Jung, Min Jung Kwon, Cheol Hun Kwak, Song I Bae, Jeong Seop Moon, Ji Won Kim, Su Hwan Kim, Kook Lae Lee
    The Korean Journal of Gastroenterology.2015; 65(1): 27.     CrossRef
  • Importance of the Time Interval between Bowel Preparation and Colonoscopy in Determining the Quality of Bowel Preparation for Full-Dose Polyethylene Glycol Preparation
    Tae Kyung Kim, Hyung Wook Kim, Su Jin Kim, Jong Kun Ha, Hyung Ha Jang, Young Mi Hong, Su Bum Park, Cheol Woong Choi, Dae Hwan Kang
    Gut and Liver.2014; 8(6): 625.     CrossRef
  • A Comparison of 2 L of Polyethylene Glycol and 45 mL of Sodium Phosphate versus 4 L of Polyethylene Glycol for Bowel Cleansing: A Prospective Randomized Trial
    Suh Eun Bae, Kyung-Jo Kim, Jun Bum Eum, Dong Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jin-Ho Kim
    Gut and Liver.2013; 7(4): 423.     CrossRef
  • A Clear Liquid Diet Is Not Mandatory for Polyethylene Glycol-Based Bowel Preparation for Afternoon Colonoscopy in Healthy Outpatients
    Yoon Suk Jung, Hyo Sun Seok, Dong Il Park, Chang Seok Song, Seong Eun Kim, Suck Ho Lee, Chang Soo Eun, Dong Soo Han, Yong Soo Kim, Chang Kyun Lee
    Gut and Liver.2013; 7(6): 681.     CrossRef
  • Comparison of Bowel Preparation Quality between Clear-liquid Diet and No Diet Restriction
    Woo Shin Jeong, Dong Il Park, Hyo Sun Seok, Seong Eun Kim, Suck-Ho Lee, Chang Kyun Lee, Chang Soo Eun, Dong Soo Han
    Intestinal Research.2012; 10(3): 272.     CrossRef
  • Comparison among Conventional 4 L Polyethylene Glycol, Split Method of 4 L Polyethylene Glycol and Combination of 2 L Polyethylene Glycol and Sodium Phosphate Solution for Colonoscopy Preparation
    So Young Jo, Nayoung Kim, Jung Won Lee, Ji Hwan Lim, Chiun Choi, Ilyoung Chon, Ho Kil, Bo Young Min, Young Sang Byoun, Ban Seok Lee, Sang Eon Jang, Hyun Kyung Park, Hyun Jin Jo, Cheol Min Shin, Sang Hyup Lee, Young Soo Park, Jin-Hyeok Hwang, Jin-Wook Kim,
    The Korean Journal of Gastroenterology.2012; 59(6): 414.     CrossRef
  • 3,187 View
  • 33 Download
  • 8 Crossref
Close layer
Intest Res : Intestinal Research
© Korean Association for the Study of Intestinal Diseases.
Close layer
TOP